Brief: Quantum Genomics Gets Approval For Firibastat Clinical Evaluation
Oct 18 (Reuters) - QUANTUM GENOMICS SA ALQGC.PA :
* OBTAINS APPROVAL FROM ETHICS COMMITTEE FOR LAUNCH CLINICAL
EVALUATION OF EXTENDED-RELEASE FIRIBASTAT TABLETS
* THE RESULTS OF THIS STUDY WILL BE AVAILABLE IN THE COURSE
OF 2
QUARTER 2019
Source text for Eikon: ID:nACT55605
Further company coverage: ALQGC.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study